PE20230408A1 - Anticuerpo anti-lilrb1 y usos del mismo - Google Patents
Anticuerpo anti-lilrb1 y usos del mismoInfo
- Publication number
- PE20230408A1 PE20230408A1 PE2022001138A PE2022001138A PE20230408A1 PE 20230408 A1 PE20230408 A1 PE 20230408A1 PE 2022001138 A PE2022001138 A PE 2022001138A PE 2022001138 A PE2022001138 A PE 2022001138A PE 20230408 A1 PE20230408 A1 PE 20230408A1
- Authority
- PE
- Peru
- Prior art keywords
- cdr
- seq
- antibody
- antigen binding
- binding fragment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Referido a anticuerpo anti-LILRB1 o fragmento de union a antigeno del mismo, que comprende regiones determinantes de complementariedad (CDR): CDR-L1 que comprende la secuencia de aminoacidos de SEQ ID NO: 1, 13, 19, 25, entre otros; una CDR-L2 que comprende SEQ ID NO: 2, 8, 14, 20, entre otros; una CDR-L3 que comprende SEQ ID NO: 3, 9, 15, 21, entre otros; una CDR-H1: que comprende SEQ ID NO: 4, 10, 16, 22; una CDR-H2 que comprende SEQ ID NO: 5, 11, 17, 23, entre otros; una CDR-H3 que comprende SEQ ID NO: 6, 12, 18, 24, entre otros. En donde el anticuerpo es IgG1 o IgG4 humano, el fragmento de union a antigeno es scFv, (scFv)2, Fab, Fab', F(ab')2, polipeptido de fusion que comprende scFv fusionado con un Fc de inmunoglobulina o polipeptido de fusion que comprende scFv fusionado con una region constante de una cadena ligera. Tambien se refiere a una composicion farmaceutica que dicho anticuerpo o fragmento de union a antigeno del mismo, molecula de acido nucleico que codifica dicho anticuerpo o fragmento de union antigeno, vector recombinante que comprende molecula de acido nucleico, una celula recombinante, un metodo para preparar dicho anticuerpo o fragmento de union a antigeno y uso del mismo en el tratamiento del cancer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190173414 | 2019-12-23 | ||
| KR20200061907 | 2020-05-22 | ||
| PCT/KR2020/018931 WO2021133036A1 (ko) | 2019-12-23 | 2020-12-22 | 항-lilrb1 항체 및 그의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230408A1 true PE20230408A1 (es) | 2023-03-07 |
Family
ID=76573198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001138A PE20230408A1 (es) | 2019-12-23 | 2020-12-22 | Anticuerpo anti-lilrb1 y usos del mismo |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12534528B2 (es) |
| EP (1) | EP4071172A4 (es) |
| JP (4) | JP7408814B2 (es) |
| KR (1) | KR102816063B1 (es) |
| CN (3) | CN114945594B (es) |
| AU (4) | AU2020415159B2 (es) |
| BR (1) | BR112022012474A2 (es) |
| CA (3) | CA3161827C (es) |
| CL (3) | CL2022001717A1 (es) |
| CO (1) | CO2022009696A2 (es) |
| IL (1) | IL294036B2 (es) |
| JO (1) | JOP20220161A1 (es) |
| MX (1) | MX2022007962A (es) |
| NZ (1) | NZ789630A (es) |
| PE (1) | PE20230408A1 (es) |
| PH (1) | PH12022551538A1 (es) |
| TW (3) | TWI824215B (es) |
| UA (1) | UA129523C2 (es) |
| WO (1) | WO2021133036A1 (es) |
| ZA (1) | ZA202206993B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022002579A2 (pt) | 2019-08-12 | 2022-06-14 | Biond Biologics Ltd | Anticorpos contra ilt2 e uso dos mesmos |
| PE20221894A1 (es) | 2020-05-01 | 2022-12-13 | Ngm Biopharmaceuticals Inc | Agentes de union a ilt y metodos para su uso |
| JP7508689B2 (ja) * | 2020-07-28 | 2024-07-01 | エルジー・ケム・リミテッド | 抗－ｌｉｌｒｂ１抗体およびその用途 |
| JP2023537396A (ja) | 2020-08-12 | 2023-08-31 | ビオンド バイオロジクス リミテッド | Ｉｌｔ２に対する抗体およびその使用 |
| US20250121104A1 (en) * | 2021-12-20 | 2025-04-17 | Fusion Pharmaceuticals Inc. | Egfr-cmet-targeted compounds and uses thereof |
| WO2023235706A1 (en) * | 2022-05-31 | 2023-12-07 | Ngm Biopharmaceuticals, Inc. | Combination therapies using ilt-binding agents and pd-1 inhibitors |
| EP4491230A1 (en) * | 2023-07-14 | 2025-01-15 | iOmx Therapeutics AG | Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof |
| KR20250129687A (ko) * | 2022-12-23 | 2025-08-29 | 아이오엠엑스 테라퓨틱스 아게 | 백혈구 면역글로불린 유사 수용체 서브패밀리 b1 (lilrb1) 및 lilrb2를 표적으로 하는 교차 특이적 항원 결합 단백질(abp), 이의 조합 및 용도 |
| WO2024207855A1 (zh) * | 2023-04-04 | 2024-10-10 | 成都优洛生物科技有限公司 | 抗lilrb1抗体或其抗原结合片段、制备方法和用途 |
| CN121358780A (zh) * | 2023-06-20 | 2026-01-16 | 科望(苏州)生物医药科技有限公司 | 与lilrb1结合的抗体或抗原结合片段及其用途 |
| WO2025259138A1 (en) * | 2024-06-13 | 2025-12-18 | Joint Stock Company "Biocad" | Monoclonal antibody to tslp and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2291405A1 (en) | 2008-05-13 | 2011-03-09 | Genentech, Inc. | ANTI-PirB ANTIBODIES |
| BR112013004389A2 (pt) | 2010-08-27 | 2016-05-17 | Pantarhei Bioscience Bv | método imunoterapêutico para tratamento do câncer de próstata |
| KR101038126B1 (ko) | 2010-11-30 | 2011-05-31 | 주식회사 엘지생명과학 | 새로운 융합 프로모터 및 이를 포함하는 재조합 벡터 |
| TW201247700A (en) | 2011-05-05 | 2012-12-01 | Baylor Res Inst | Immunoglobulin-like transcript (ILT) receptors as CD8 antagonists |
| US20150174203A1 (en) * | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
| US10550187B2 (en) * | 2014-10-24 | 2020-02-04 | Incept, Llc | Extra luminal scaffold |
| US10316094B2 (en) | 2014-10-24 | 2019-06-11 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance |
| CA2977544C (en) | 2015-03-06 | 2023-12-19 | The Board Of Regents Of The University Of Texas System | Anti-lilrb antibodies and their use in detecting and treating cancer |
| TWI773647B (zh) | 2015-06-23 | 2022-08-11 | 史隆凱特林紀念癌症中心 | 新穎pd-1免疫調控劑 |
| JP7165717B2 (ja) | 2017-03-15 | 2022-11-04 | パンディオン・オペレーションズ・インコーポレイテッド | 標的免疫寛容 |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| US20210122819A1 (en) * | 2018-01-18 | 2021-04-29 | Adanate, Inc. | Anti-lilrb antibodies and uses thereof |
| JP2022516140A (ja) | 2018-12-26 | 2022-02-24 | インネート・ファルマ | 白血球免疫グロブリン様受容体２中和抗体 |
-
2020
- 2020-12-22 EP EP20907118.2A patent/EP4071172A4/en active Pending
- 2020-12-22 TW TW109145586A patent/TWI824215B/zh active
- 2020-12-22 WO PCT/KR2020/018931 patent/WO2021133036A1/ko not_active Ceased
- 2020-12-22 PE PE2022001138A patent/PE20230408A1/es unknown
- 2020-12-22 CN CN202080087379.8A patent/CN114945594B/zh active Active
- 2020-12-22 PH PH1/2022/551538A patent/PH12022551538A1/en unknown
- 2020-12-22 MX MX2022007962A patent/MX2022007962A/es unknown
- 2020-12-22 BR BR112022012474A patent/BR112022012474A2/pt unknown
- 2020-12-22 AU AU2020415159A patent/AU2020415159B2/en active Active
- 2020-12-22 TW TW112125634A patent/TWI871698B/zh active
- 2020-12-22 CN CN202411482234.4A patent/CN119241708A/zh active Pending
- 2020-12-22 NZ NZ789630A patent/NZ789630A/en unknown
- 2020-12-22 CA CA3161827A patent/CA3161827C/en active Active
- 2020-12-22 UA UAA202202636A patent/UA129523C2/uk unknown
- 2020-12-22 CA CA3269788A patent/CA3269788A1/en active Pending
- 2020-12-22 JO JOP/2022/0161A patent/JOP20220161A1/ar unknown
- 2020-12-22 IL IL294036A patent/IL294036B2/en unknown
- 2020-12-22 KR KR1020200181311A patent/KR102816063B1/ko active Active
- 2020-12-22 CN CN202411481892.1A patent/CN119219779A/zh active Pending
- 2020-12-22 JP JP2022538832A patent/JP7408814B2/ja active Active
- 2020-12-22 TW TW112125633A patent/TWI866327B/zh active
- 2020-12-22 CA CA3265597A patent/CA3265597A1/en active Pending
- 2020-12-22 US US17/788,493 patent/US12534528B2/en active Active
-
2022
- 2022-06-22 CL CL2022001717A patent/CL2022001717A1/es unknown
- 2022-06-23 ZA ZA2022/06993A patent/ZA202206993B/en unknown
- 2022-07-11 CO CONC2022/0009696A patent/CO2022009696A2/es unknown
-
2023
- 2023-12-19 JP JP2023213951A patent/JP7674458B2/ja active Active
- 2023-12-19 JP JP2023213950A patent/JP7674039B2/ja active Active
-
2025
- 2025-02-11 CL CL2025000404A patent/CL2025000404A1/es unknown
- 2025-02-11 CL CL2025000403A patent/CL2025000403A1/es unknown
- 2025-03-13 AU AU2025201828A patent/AU2025201828A1/en active Pending
- 2025-03-13 AU AU2025201829A patent/AU2025201829A1/en active Pending
- 2025-04-08 AU AU2025202487A patent/AU2025202487A1/en active Pending
- 2025-04-22 JP JP2025070437A patent/JP2025108694A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230408A1 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| US20220403028A1 (en) | Novel anti-cd3 antibodies | |
| JP7257971B6 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| RU2018146050A (ru) | Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген | |
| RU2017137010A (ru) | Анти-сеасам6 антитела и их применения | |
| KR102754842B1 (ko) | 신규 항 hsa 항체 | |
| NZ717476A (en) | Anti-garp protein and uses thereof | |
| CN104903352A (zh) | 多价结合蛋白组合物 | |
| AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| CN111225926B (zh) | 靶向pdl1的抗体及其使用方法 | |
| WO2018224439A1 (en) | Novel anti-hsa antibodies | |
| WO2019199916A1 (en) | Fab-based trispecific antibodies | |
| WO2018224441A1 (en) | Novel anti-cd3 antibodies | |
| CN115746144B (zh) | 抗tigit-pd1双特异性抗体及其应用 | |
| CN119213023A (zh) | Ilt3和cd3结合剂以及其使用方法 | |
| RU2010122044A (ru) | УЛУЧШЕННЫЕ МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Nogo-А И ИХ ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ | |
| CA3173980A1 (en) | Anti-cd19 antibodies and methods of using and making thereof | |
| AR132623A1 (es) | PROTEÍNAS DE FUSIÓN DE INTERFERÓN a DIRIGIDAS Y MÉTODOS DE USO | |
| KR20250091367A (ko) | 개 pdl-1 항체 및 이의 용도 | |
| RU2025133788A (ru) | Нацеленные слитые белки на основе интерферона альфа и способы их применения | |
| CN120225557A (zh) | 特异于跨膜激活物和caml相互作用物(taci)的抗原结合蛋白 | |
| JP2025516805A (ja) | 固形腫瘍を治療する方法 | |
| HK40027107B (en) | Anti‑cd3 epsilon antibodies | |
| HK40027107A (en) | Anti‑cd3 epsilon antibodies |